REG - Malin Corp PLC - Poseida Collaboration Agreement with Astellas

MalinAnnouncement

01/05/2024 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240501:nRSA8940Ma&default-theme=true

RNS Number : 8940M  Malin Corporation PLC  01 May 2024

Malin Corporation plc

 

Poseida Therapeutics Announces Research Collaboration and Licensing Agreement
with Astellas

Dublin-Ireland, 1 May 2024: Malin Corporation plc. (Euronext Growth
Dublin:MLC) (Malin), a company investing in highly innovative life sciences
companies, notes that its investee company, Poseida Therapeutics, Inc.
(Poseida), has announced that it has entered into a research collaboration and
licensing agreement with Xyphos Biosciences Inc. (a wholly owned subsidiary of
Astellas Pharma Inc.) (Xyphos) to develop novel convertibleCAR® programs by
combining the innovative cell therapy platforms from each of the companies.

Under the terms of the agreement, the companies plan to
combine Poseida's proprietary allogeneic CAR-T platform with Xyphos'
ACCEL™ technology to create one Poseida-developed CAR-T construct to form
the basis of two convertibleCAR® product candidates targeting solid
tumours.

Xyphos will reimburse Poseida for costs incurred as part of the research
agreement and will be responsible for the development and future
commercialisation of products generated from the collaboration. Poseida will
receive US $50 million upfront plus potential development and sales
milestones and contingency payments of up to US $550 million in total.
Additionally, Poseida is eligible for up to low double digit tiered
royalties as a percentage of net sales.

 

A copy of Poseida's press release is available to view here: Poseida Press
Release 1 May 2024
(https://investors.poseida.com/news-releases/news-release-details/astellas-and-poseida-therapeutics-enter-research-collaboration)
.

 

ENDS

 

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative
life sciences companies. Its purpose is to create shareholder value through
the application of long-term capital and operational and strategic expertise
to a diverse range of global healthcare businesses. Malin has a focus on
innovative businesses underpinned by exceptional science and works with its
investee companies, providing strategic and financial support to enable them
to reach their value potential. Malin is headquartered and domiciled in
Ireland and listed on the Euronext Growth Dublin. For more information
visit www.malinplc.com (http://www.malinplc.com/)

For further information please contact:

 

Malin

Fiona Dunlevy, Company Secretary

Tel: +353 (0)1 901 5700

cosec@malinplc.com (mailto:cosec@malinplc.com)

 

Davy Corporate Finance (Euronext Growth Listing Sponsor & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

 

Liberum (Joint Broker)

Phil Walker / Ben Cryer

Tel: +44 (0) 20 3100 2000

 

Powerscourt (Media enquiries)

Eavan Gannon

Tel: +353 87 236 5973

malin@powerscourt-group.com (mailto:malin@powerscourt-group.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAKSFEFELEFA